1-[5-(3-morpholin-4-ylpropyl)-6-oxo-5-(trifluoromethyl)cyclohexa-1,3-dien-1-yl]-2H-pyridine-3,5-dicarboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-[5-(3-morpholin-4-ylpropyl)-6-oxo-5-(trifluoromethyl)cyclohexa-1,3-dien-1-yl]-2H-pyridine-3,5-dicarboxamide
• 化学式: C₂₁H₂₅F₃N₄O₄
• 分子量: 454.4
• InChiKey: GVJMHJJEOFYLNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS
  申请人：Genoa Pharmaceuticals, Inc.

  公开号：EP2877164A2

  公开（公告）日：2015-06-03
• [EN] AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ANALOGUES DE PIRFÉNIDONE ET DE PYRIDONE POUR AÉROSOL ET LEURS UTILISATIONS
  申请人：GENOA PHARMACEUTICALS INC

  公开号：WO2014018668A2

  公开（公告）日：2014-01-30

  Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.